GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing King-Friend Biochemical Pharmaceutical Co Ltd (SHSE:603707) » Definitions » Construction In Progress

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Construction In Progress : ¥83 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nanjing King-Friend Biochemical Pharmaceutical Co Construction In Progress?

Nanjing King-Friend Biochemical Pharmaceutical Co's quarterly construction in progress increased from Sep. 2023 (¥26 Mil) to Dec. 2023 (¥80 Mil) and increased from Dec. 2023 (¥80 Mil) to Mar. 2024 (¥83 Mil).

Nanjing King-Friend Biochemical Pharmaceutical Co's annual construction in progress increased from Dec. 2021 (¥215 Mil) to Dec. 2022 (¥251 Mil) but then declined from Dec. 2022 (¥251 Mil) to Dec. 2023 (¥80 Mil).


Nanjing King-Friend Biochemical Pharmaceutical Co Construction In Progress Historical Data

The historical data trend for Nanjing King-Friend Biochemical Pharmaceutical Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing King-Friend Biochemical Pharmaceutical Co Construction In Progress Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.00 99.68 215.26 250.62 79.74

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 281.28 18.12 25.57 79.74 83.00

Nanjing King-Friend Biochemical Pharmaceutical Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Business Description

Traded in Other Exchanges
N/A
Address
1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
Executives
Huang Xi Wei Director
Liu Zu Qing Supervisors
Xie Ju Hua Director
Wu Gui Ping senior management
Tang Yong Qun Director
Qian Xiao Jie senior management

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Headlines

No Headlines